What you can expect to pay

Published tariffs for ChondroFiller™ in the UK follow a three-tier structure determined by the surface area of the cartilage defect being treated, not by procedure complexity alone. One box of the collagen scaffold — suitable for defects up to approximately 3 cm² — is priced at £3,000. Where the defect is larger, two boxes covering up to around 4.5 cm² cost £5,500, and three boxes for defects up to roughly 6 cm² cost £8,000. Severe or multi-compartment presentations may reach £9,800.

For most people, the lowest band is the most relevant figure. The majority of patients presenting with a single focal cartilage defect are treated with one box, placing them in the £3,000 tier.

It is worth noting that the applicable tier cannot be decided by the patient in advance. A consultant must review MRI or ultrasound imaging to confirm the defect's dimensions before the correct tier can be confirmed — meaning an accurate cost can only be given following that imaging assessment.

These figures are fully bundled. The published price at each tier covers the pre-injection consultation, imaging review, real-time ultrasound-guided placement, the ChondroFiller™ product itself, intravenous antibiotic cover, and a six-week follow-up appointment, with no additional line items billed separately.

What the price covers

The distinction matters in practice. Standard UK private musculoskeletal care typically bills imaging, the procedure, and follow-up appointments as separate line items — meaning a quoted "procedure cost" can grow by several hundred pounds once those elements are counted individually. The bundled structure here is different: the fee confirmed at assessment should reflect the total due across the entire pathway, with no further charges added as individual appointments are completed.

It is also worth understanding what sits behind the headline figure. ChondroFiller™ is a Class III medical device — the highest regulatory tier for implantable products in the UK and EU — manufactured in Germany and supplied under prescription. The unit cost of the implant itself, rather than professional fees or clinic overheads alone, is the primary driver of the overall price. This explains why the starting point is higher than a standard visco-supplementation or corticosteroid injection, which carry no equivalent device-classification costs.

Before committing, ask the provider to confirm in writing that the quoted fee is fully inclusive and to specify any circumstances in which additional costs might arise — for example, if clinical findings on the day of treatment differ from the imaging assessment. This is standard due diligence with any private medical procedure and removes ambiguity on both sides.

How ChondroFiller™ sits in the broader cost landscape

Placed alongside the wider range of UK cartilage regeneration options, ChondroFiller™ sits broadly in the lower-to-middle part of the market. For context, microfracture — a surgical procedure requiring operating theatre admission — carries a typical private cost of around £4,000. At the other end of the scale, single-stage cartilage implantation procedures can reach approximately £28,000. ChondroFiller™'s £3,000 starting point and £8,000 upper band occupy the space between those two surgical alternatives.

For patients exploring combination pathways, adding Arthrosamid® (a polyacrylamide hydrogel designed to cushion rather than regenerate) brings the total to around £6,000; a more intensive biological pathway incorporating autologous mesenchymal stem cells is priced at approximately £11,000.

Beyond the headline numbers, there is a pathway difference worth keeping in mind. Microfracture and single-stage implantation both involve operating theatre admission, general or regional anaesthesia, and a surgical recovery period. ChondroFiller™ is delivered as an outpatient ultrasound-guided injection — a clinically different proposition, not merely a cheaper one. Whether that distinction is relevant depends on individual clinical presentation, which a consultant assessment will determine.

Why ChondroFiller™ is not available on the NHS

Straightforward to answer: as of mid-2026, ChondroFiller™ carries no NHS commissioning decision and has not been through a NICE technology appraisal. NHS hospitals do not stock the product, and no GP referral route exists. Patients cannot access it through the public system in any form at present.

This is not unusual for a recently introduced device. CE-marked Class III medical devices — the highest regulatory tier for implantable products — are permitted to enter UK private practice without first completing a NICE review. ChondroFiller™ has followed that route since its UK introduction, which means it became available privately before any public-funding assessment was initiated. Given that no appraisal has yet been submitted, NHS commissioning in the near term is considered improbable.

For readers wondering whether the NHS offers an equivalent, the only biological cartilage cell therapy currently commissioned by NHS England is Autologous Chondrocyte Implantation (ACI) — a multi-stage surgical procedure involving cell harvesting, laboratory expansion, and a subsequent implantation operation. ACI and ChondroFiller™ address overlapping clinical presentations by entirely different means; they are not interchangeable from either a procedural or a funding standpoint.

The practical conclusion is straightforward: for anyone with a focal cartilage defect who is considering ChondroFiller™, this remains a self-funded private pathway. For the foreseeable future, that structural reality is unlikely to change.

Insurance coverage — what to ask your insurer

Private medical insurance is unlikely to list ChondroFiller™ as a named benefit in a standard policy schedule, but that does not mean the door is closed. Case-by-case pre-authorisation approvals have been reported — most commonly through Bupa, Aviva, and WPA — and even a partial approval can reduce the out-of-pocket cost meaningfully.

The billing codes that make this conversation possible are CCSD W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy). Providing both codes when you contact your insurer gives the claims assessor something specific to search against; without them, a standard policy inquiry may not surface the relevant benefit or exclusion.

When partial coverage is approved, it tends to mean the insurer funds the procedural elements — such as the consultation, imaging review, or the CCSD-coded clinical fees — while the cost of the Class III implant unit itself falls outside the covered benefit. Since the implant is the primary cost driver within each pricing tier, it is worth asking specifically whether the product cost is assessed separately or treated as an excluded item from the outset.

Written pre-authorisation must be obtained before the appointment is confirmed. Retrospective claims — submitted after the procedure has taken place — are rarely approved by UK insurers, even where verbal agreement appeared to be given. Verbal confirmation is not a binding commitment.

The insurer list above reflects approvals reported as of October 2025. Policies evolve and individual terms vary considerably, so verifying current coverage directly with your provider before any decision is the only reliable step.

When costs are higher — combination pathways

For patients with more complex presentations — where a single focal defect is not the whole picture — the pricing structure extends beyond the three-tier model covered in the opening section.

Adding Arthrosamid® to the same appointment creates a combination pathway priced at approximately £6,000. The two products serve distinct roles: Arthrosamid is a non-regenerative polyacrylamide hydrogel designed to modify the joint environment, while ChondroFiller™ is a regenerative collagen scaffold targeting the defect itself. Their combination reflects a mechanistic rationale — addressing both the cartilage lesion and broader joint factors simultaneously — rather than straightforward cost stacking.

A further step involves including autologous mesenchymal stem cell preparation alongside both injectables; this three-component pathway can reach approximately £11,000. As with the standard tiers, which combination applies is determined by imaging and clinical assessment — eligibility is not something patients can self-assign in advance.

Most people reading this section will not need it. Combination pathways represent the upper ceiling of what ChondroFiller™ treatment can cost in the UK, and the clinical picture for most presenting patients does not extend that far.